2017
Predictors of Left Ventricular Ejection Fraction Improvement After Primary Stenting in ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial)
Serrao GW, Lansky AJ, Mehran R, Stone GW. Predictors of Left Ventricular Ejection Fraction Improvement After Primary Stenting in ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). The American Journal Of Cardiology 2017, 121: 678-683. PMID: 29394998, DOI: 10.1016/j.amjcard.2017.12.004.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntithrombinsBiomarkersCoronary AngiographyFemaleHeparinHirudinsHumansMaleMiddle AgedPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexPredictive Value of TestsRecombinant ProteinsRisk AssessmentRisk FactorsST Elevation Myocardial InfarctionStentsStroke VolumeTreatment OutcomeVentricular Dysfunction, LeftConceptsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionLeft ventricular ejection fractionPrimary PCIAcute Myocardial Infarction trialMyocardial Infarction trialElevation myocardial infarctionHarmonizing OutcomesLVEF improvementMyocardial infarctionLower baseline left ventricular ejection fractionLeft ventricular ejection fraction improvementBaseline left ventricular ejection fractionGlycoprotein IIb/IIIa inhibitorsVentricular ejection fraction improvementMyocardial Infarction 3 flowIIb/IIIa inhibitorsEjection fraction improvementHalf of patientsPercutaneous coronary interventionVentricular ejection fractionPredictors of improvementPrespecified substudyPrimary stentingAngiographic predictors
2016
Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials
Giustino G, Mehran R, Bansilal S, Feit F, Lincoff M, Deliargyris EN, Kirtane AJ, Généreux P, Redfors B, Prats J, Bernstein D, Brener SJ, Skerjanec S, Lansky AJ, Francese DP, Dangas GD, Stone GW. Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials. The American Journal Of Cardiology 2016, 118: 6-16. PMID: 27181566, DOI: 10.1016/j.amjcard.2016.04.005.Peer-Reviewed Original ResearchConceptsGlycoprotein IIb/IIIa inhibitorsPercutaneous coronary interventionMajor adverse cardiac eventsEfficacy of bivalirudinAdverse cardiac eventsDiabetes mellitusMajor bleedingCoronary interventionBivalirudin treatmentCause mortalityCardiac eventsNon-coronary artery bypass graft-related major bleedingPrimary efficacy end pointPrimary safety end pointUrgent Intervention Triage StrategyAcute Myocardial Infarction trialIIb/IIIa inhibitorsEnd pointHORIZONS-AMI trialPCI Linking AngiomaxComposite of deathEfficacy end pointMyocardial Infarction trialSafety end pointPatient-level data
2014
Prognostic Value of Angiographic Lesion Complexity in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial)
Goto K, Lansky AJ, Ng VG, Pietras C, Nargileci E, Mehran R, Parise H, Feit F, Ohman EM, White HD, Bertrand ME, Desmet W, Hamon M, Stone GW. Prognostic Value of Angiographic Lesion Complexity in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). The American Journal Of Cardiology 2014, 114: 1638-1645. PMID: 25312637, DOI: 10.1016/j.amjcard.2014.09.003.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAnticoagulantsCoronary AngiographyCoronary Artery DiseaseFemaleHemorrhageHeparinHirudinsHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial RevascularizationOdds RatioPeptide FragmentsPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexPrognosisRecombinant ProteinsSeverity of Illness IndexTreatment OutcomeConceptsPercutaneous coronary interventionAcute coronary syndromeType C lesionsGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsC lesionsLesion complexityBivalirudin monotherapyComposite ischemiaCoronary syndromeCoronary interventionIschemic eventsMyocardial infarctionCardiology/American Heart Association classificationAdverse short-term prognosisAmerican Heart Association classificationAdverse ischemic eventsComposite ischemic eventsContemporary interventional therapyMajor bleeding complicationsMajor hemorrhagic complicationsShort-term prognosisAcute CatheterizationAntithrombotic regimensMajor bleedingSex‐based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: Three year results from the HORIZONS‐AMI trial
Yu J, Mehran R, Grinfeld L, Xu K, Nikolsky E, Brodie BR, Witzenbichler B, Kornowski R, Dangas GD, Lansky AJ, Stone GW. Sex‐based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: Three year results from the HORIZONS‐AMI trial. Catheterization And Cardiovascular Interventions 2014, 85: 359-368. PMID: 25115966, DOI: 10.1002/ccd.25630.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsChi-Square DistributionFemaleHealth Status DisparitiesHemorrhageHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionOdds RatioPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsProportional Hazards ModelsProspective StudiesRisk FactorsSex FactorsStentsTime FactorsTreatment OutcomeConceptsMajor adverse cardiac eventsPrimary percutaneous coronary interventionMajor bleedingFemale sexRisk of MACEST-segment elevation myocardial infarction (STEMI) managementGlycoprotein IIb/IIIa inhibitorsAcute Myocardial Infarction trialIIb/IIIa inhibitorsHr of onsetAdverse cardiac eventsMyocardial Infarction trialHigh-risk subsetPresence of comorbiditiesMyocardial infarction managementPercutaneous coronary interventionBare metal stentsSex-based disparitiesFurther dedicated studiesLong-term managementHarmonizing OutcomesCardiac eventsCoronary interventionIschemic eventsSymptom onset
2013
Predictors of suboptimal TIMI flow after primary angioplasty for acute myocardial infarction: results from the HORIZONS-AMI trial.
Caixeta A, Lansky AJ, Mehran R, Brener SJ, Claessen B, Généreux P, Palmerini T, Witzenbichler B, Guagliumi G, Brodie BR, Dudek D, Fahy M, Dangas GD, Stone GW. Predictors of suboptimal TIMI flow after primary angioplasty for acute myocardial infarction: results from the HORIZONS-AMI trial. EuroIntervention 2013, 9: 220-7. PMID: 23518872, DOI: 10.4244/eijv9i2a37.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAngioplasty, Balloon, CoronaryAntithrombinsChi-Square DistributionCoronary AngiographyCoronary CirculationFemaleHumansKaplan-Meier EstimateLogistic ModelsMaleMiddle AgedMyocardial InfarctionOdds RatioPlatelet Aggregation InhibitorsPredictive Value of TestsProportional Hazards ModelsProspective StudiesRecovery of FunctionRisk FactorsTime FactorsTreatment OutcomeConceptsTIMI 3 flowFinal TIMI 3 flowHORIZONS-AMI trialAcute myocardial infarctionPrimary PCITIMI flowMyocardial infarctionGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsNormal TIMI flowThree-year mortalityMulticentre prospective studyPatient-related factorsBaseline TIMIAngiographic factorsPrimary angioplastyIndependent predictorsUnfractionated heparinProspective studyAnterior MIAnatomical factorsPatientsTIMICore labLesion length
2012
Clinical Outcomes Following Stent Thrombosis Occurring In-Hospital Versus Out-of-Hospital Results From the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) Trial
Dangas GD, Claessen BE, Mehran R, Brener S, Brodie BR, Dudek D, Witzenbichler B, Peruga JZ, Guagliumi G, Moses JW, Lansky AJ, Xu K, Stone GW. Clinical Outcomes Following Stent Thrombosis Occurring In-Hospital Versus Out-of-Hospital Results From the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) Trial. Journal Of The American College Of Cardiology 2012, 59: 1752-1759. PMID: 22575312, DOI: 10.1016/j.jacc.2011.12.042.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionHospital stent thrombosisPrimary percutaneous coronary interventionGlycoprotein IIb/IIIa inhibitorsHORIZONS-AMI trialStent thrombosisMajor bleedingClinical outcomesUnfractionated heparinMyocardial infarctionST eventsPrimary PCIIIb/IIIa inhibitorsProbable stent thrombosisAcademic Research ConsortiumElevation myocardial infarctionPercutaneous coronary interventionSTEMI patientsCoronary interventionHospital phaseBetter prognosisMultivariable analysisReperfusion resultsSubgroup analysisMost deathsPrognostic Significance of Elevated Baseline Troponin in Patients With Acute Coronary Syndromes and Chronic Kidney Disease Treated With Different Antithrombotic Regimens
Acharji S, Baber U, Mehran R, Fahy M, Kirtane AJ, Lansky AJ, Stone GW. Prognostic Significance of Elevated Baseline Troponin in Patients With Acute Coronary Syndromes and Chronic Kidney Disease Treated With Different Antithrombotic Regimens. Circulation Cardiovascular Interventions 2012, 5: 157-165. PMID: 22354934, DOI: 10.1161/circinterventions.111.963876.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAged, 80 and overBiomarkersFemaleFibrinolytic AgentsFollow-Up StudiesHeparinHirudinsHumansKidney Failure, ChronicMaleMyocardial InfarctionPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexPrognosisRecombinant ProteinsReference StandardsSurvival AnalysisTroponin TConceptsGlycoprotein IIb/IIIa inhibitorsAcute coronary syndromeBaseline troponin elevationChronic kidney diseaseMajor adverse cardiac eventsTroponin elevationMyocardial infarctionBivalirudin monotherapyMajor bleedingCKD patientsCoronary syndromeBaseline troponinKidney diseaseHigh-risk acute coronary syndromesIIb/IIIa inhibitorsLong-term clinical outcomesBaseline cardiac troponinBaseline troponin levelsDifferent antithrombotic regimensAdverse cardiac eventsACS patientsACUITY trialAntithrombotic regimensComposite deathRandomization arm
2011
Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
Saltzman AJ, Stone GW, Claessen BE, Narula A, Leon-Reyes S, Weisz G, Brodie B, Witzenbichler B, Guagliumi G, Kornowski R, Dudek D, Metzger DC, Lansky AJ, Nikolsky E, Dangas GD, Mehran R. Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2011, 4: 1011-1019. PMID: 21939942, DOI: 10.1016/j.jcin.2011.06.012.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsChi-Square DistributionChronic DiseaseDrug-Eluting StentsEuropeFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansIsraelKaplan-Meier EstimateKidney DiseasesMaleMetalsMiddle AgedMyocardial InfarctionPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProportional Hazards ModelsProspective StudiesProsthesis DesignRecombinant ProteinsRecurrenceRisk AssessmentRisk FactorsStentsStrokeThrombosisTime FactorsTreatment OutcomeUnited StatesConceptsST-segment elevation myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary percutaneous coronary interventionNet adverse cardiac eventsChronic kidney diseasePercutaneous coronary interventionTarget vessel revascularizationBare metal stentsDrug-eluting stentsHORIZONS-AMI trialElevation myocardial infarctionMajor bleedingBivalirudin monotherapyCoronary interventionKidney diseaseMyocardial infarctionRate of TVRIschemia-driven target vessel revascularizationNon-coronary artery bypassIIb/IIIa inhibitorsBenefit of bivalirudinDifferent antithrombotic strategiesAdverse cardiac eventsComposite of deathHigh rateImpact of Smoking on Outcomes of Patients With ST-Segment Elevation Myocardial Infarction (from the HORIZONS-AMI Trial)
Goto K, Nikolsky E, Lansky AJ, Dangas G, Witzenbichler B, Parise H, Guagliumi G, Kornowski R, Claessen BE, Fahy M, Mehran R, Stone GW. Impact of Smoking on Outcomes of Patients With ST-Segment Elevation Myocardial Infarction (from the HORIZONS-AMI Trial). The American Journal Of Cardiology 2011, 108: 1387-1394. PMID: 21864816, DOI: 10.1016/j.amjcard.2011.06.063.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAntithrombinsCoronary AngiographyCoronary RestenosisCoronary ThrombosisDrug Therapy, CombinationDrug UtilizationFemaleHemorrhageHeparinHirudinsHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPaclitaxelPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexPyridinesRecombinant ProteinsSmokingStentsConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionElevation myocardial infarctionPrimary percutaneous coronary interventionProbable stent thrombosisPercutaneous coronary interventionUnfractionated heparinStent thrombosisMajor bleedingMyocardial infarctionBivalirudin monotherapyCoronary interventionSmoking statusPaclitaxel-eluting stent implantationIIb/IIIa inhibitorsAlternative antithrombotic regimensHORIZONS-AMI trialOutcomes of patientsImpact of smokingPaclitaxel-eluting stentsBare metal stentsLate stent thrombosisAntithrombotic regimensIschemic eventsIndependent predictorsImpact of Bleeding on Mortality After Percutaneous Coronary Intervention Results From a Patient-Level Pooled Analysis of the REPLACE-2 (Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events), ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy), and HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trials
Mehran R, Pocock S, Nikolsky E, Dangas GD, Clayton T, Claessen BE, Caixeta A, Feit F, Manoukian SV, White H, Bertrand M, Ohman EM, Parise H, Lansky AJ, Lincoff AM, Stone GW. Impact of Bleeding on Mortality After Percutaneous Coronary Intervention Results From a Patient-Level Pooled Analysis of the REPLACE-2 (Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events), ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy), and HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trials. JACC Cardiovascular Interventions 2011, 4: 654-664. PMID: 21700252, DOI: 10.1016/j.jcin.2011.02.011.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAntithrombinsConfidence IntervalsCoronary Artery DiseaseDrug-Eluting StentsFemaleHealth Status IndicatorsHemorrhageHeparinHirudinsHumansLogistic ModelsMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial ReperfusionPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexRandomized Controlled Trials as TopicRecombinant ProteinsRisk AssessmentRisk FactorsTriageConceptsPercutaneous coronary interventionTIMI major bleedingPatient-level pooled analysisHORIZONS-AMI trialMajor bleedingBlood transfusionSubsequent mortalityRisk scoreHazard ratioIndependent predictorsPooled analysisGlycoprotein IIb/IIIa inhibitorsPercutaneous Coronary Intervention ResultsIIb/IIIa inhibitorsMajor bleeding ratesTIMI major bleedTIMI minor bleedingRespective hazard ratiosArtery bypass graftRisk score groupsHigh-risk groupRisk of patientsIsolated hematomasMajor bleedsLate mortalityEffect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis
Dangas GD, Mehran R, Nikolsky E, Claessen BE, Lansky AJ, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Möckel M, Caixeta A, Parise H, White H, Stone GW, Investigators H. Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis. Journal Of The American College Of Cardiology 2011, 57: 2309-2316. PMID: 21636031, DOI: 10.1016/j.jacc.2011.01.038.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionElevation myocardial infarctionMajor bleedingMyocardial infarctionCardiac mortalityAcute ST-segment elevation myocardial infarctionST-segment elevation myocardial infarction (STEMI) patientsPrimary Percutaneous Coronary Intervention ResultsGlycoprotein IIb/IIIa inhibitorsPercutaneous Coronary Intervention ResultsElevation myocardial infarction patientsPrimary percutaneous coronary interventionIIb/IIIa inhibitorsBenefit of bivalirudinLate cardiac survivalProbable stent thrombosisPercutaneous coronary interventionTwo-year rateAcute myocardial infarctionMyocardial infarction patientsHORIZONS-AMISwitch patientsPrimary angioplastyControl patientsCoronary interventionFrequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction
Dangas GD, Caixeta A, Mehran R, Parise H, Lansky AJ, Cristea E, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Möeckel M, Stone GW. Frequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction. Circulation 2011, 123: 1745-1756. PMID: 21482968, DOI: 10.1161/circulationaha.110.981688.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAnticoagulantsAntithrombinsClopidogrelCoronary RestenosisCoronary ThrombosisDrug Therapy, CombinationDrug-Eluting StentsFemaleHeparinHirudinsHumansMaleMetalsMiddle AgedMyocardial InfarctionPaclitaxelPeptide FragmentsPlatelet Aggregation InhibitorsPredictive Value of TestsRecombinant ProteinsRisk FactorsTiclopidineTreatment OutcomeTubulin ModulatorsConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionElevation myocardial infarctionPercutaneous coronary interventionBare metal stentsDrug-eluting stentsStent thrombosisCoronary interventionMyocardial infarctionMetal stentsBivalirudin monotherapyOnly bare-metal stentsAcute Myocardial Infarction trialIIb/IIIa inhibitorsClopidogrel loading dosePotent antiplatelet therapyProbable stent thrombosisAcute stent thrombosisMyocardial Infarction trialAcute myocardial infarctionAntithrombin therapyHarmonizing OutcomesAntiplatelet therapyIndependent predictorsIncidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: Results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial
Caixeta A, Dangas GD, Mehran R, Feit F, Nikolsky E, Lansky AJ, Aoki J, Moses JW, Steinhubl SR, White HD, Ohman EM, Manoukian SV, Fahy M, Stone GW. Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: Results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. American Heart Journal 2011, 161: 298-306.e1. PMID: 21315212, DOI: 10.1016/j.ahj.2010.10.035.Peer-Reviewed Original ResearchConceptsIIb/IIIa inhibitorsGP IIb/IIIa inhibitorsAcute coronary syndromeBivalirudin monotherapyMajor bleedingCoronary syndromePlatelet countClinical consequencesUrgent Intervention Triage Strategy (ACUITY) trialGlycoprotein IIb/IIIa inhibitorsPredictors of mortalityAcquired thrombocytopeniaACUITY trialAcute CatheterizationAntiplatelet medicationsAntithrombotic therapyIschemic complicationsAnticoagulant regimenIndependent predictorsStrategy trialThrombocytopeniaPatientsMultivariate analysisMonotherapyLess decline
2010
Impact of Bivalirudin Therapy in High-Risk Patients With Acute Myocardial Infarction 1-Year Results From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial
Parodi G, Antoniucci D, Nikolsky E, Witzenbichler B, Guagliumi G, Peruga JZ, Stuckey T, Dudek D, Kornowski R, Hartmann F, Lansky AJ, Mehran R, Stone GW. Impact of Bivalirudin Therapy in High-Risk Patients With Acute Myocardial Infarction 1-Year Results From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2010, 3: 796-802. PMID: 20723849, DOI: 10.1016/j.jcin.2010.05.009.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAntithrombinsChi-Square DistributionEptifibatideEuropeFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansImmunoglobulin Fab FragmentsIsraelKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPatient SelectionPeptide FragmentsPeptidesPlatelet Aggregation InhibitorsProspective StudiesRecombinant ProteinsRisk AssessmentRisk FactorsSecondary PreventionStentsTime FactorsTreatment OutcomeUnited StatesConceptsGlycoprotein IIb/IIIa inhibitorsHORIZONS-AMI trialHigh-risk patientsAcute myocardial infarctionRecurrent myocardial infarctionUnfractionated heparinMyocardial infarctionHigh riskPrimary percutaneous coronary interventionIIb/IIIa inhibitorsBaseline patient riskCADILLAC risk scoreIntermediate-risk groupPrimary percutaneous interventionPercutaneous coronary interventionHigh-risk groupLow-risk groupBivalirudin therapyMajor bleedingTrial patientsCoronary interventionIntermediate riskClinical variablesPercutaneous interventionPatient riskComparison of Catheterization Laboratory Initiated Abciximab and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes (an ACUITY Substudy)
Kirtane AJ, Parise H, Mehran R, Moses JW, Fahy M, Bertrand ME, Ohman EM, White HD, Feit F, Colombo A, McLaurin BT, Cox DA, Ware JH, Pocock SJ, Lansky AJ, Stone GW. Comparison of Catheterization Laboratory Initiated Abciximab and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes (an ACUITY Substudy). The American Journal Of Cardiology 2010, 106: 180-186. PMID: 20599000, DOI: 10.1016/j.amjcard.2010.03.015.Peer-Reviewed Original ResearchConceptsAcute coronary syndromePercutaneous coronary interventionCoronary syndromeCoronary interventionTreatment selectionHigh-risk acute coronary syndromesUrgent Intervention Triage Strategy (ACUITY) trialGlycoprotein IIb/IIIa inhibitorsBaseline cardiac risk factorsNet clinical adverse eventsIIb/IIIa inhibitorsPrevious revascularization proceduresUse of abciximabCardiac risk factorsStudy end pointClinical adverse eventsImproved clinical outcomesST-segment deviationAcute CatheterizationComposite ischemiaMajor bleedingIschemic complicationsAdverse eventsBiomarker elevationRevascularization proceduresImpact of Anemia on Clinical Outcomes of Patients With ST-Segment Elevation Myocardial Infarction in Relation to Gender and Adjunctive Antithrombotic Therapy (from the HORIZONS-AMI Trial)
Tsujita K, Nikolsky E, Lansky AJ, Dangas G, Fahy M, Brodie BR, Dudek D, Möckel M, Ochala A, Mehran R, Stone GW. Impact of Anemia on Clinical Outcomes of Patients With ST-Segment Elevation Myocardial Infarction in Relation to Gender and Adjunctive Antithrombotic Therapy (from the HORIZONS-AMI Trial). The American Journal Of Cardiology 2010, 105: 1385-1394. PMID: 20451683, DOI: 10.1016/j.amjcard.2010.01.001.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnemiaAngioplasty, Balloon, CoronaryCombined Modality TherapyDrug Therapy, CombinationElectrocardiographyFemaleFibrinolytic AgentsFollow-Up StudiesHeparinHirudinsHospital MortalityHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionNeoadjuvant TherapyPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexProbabilityProportional Hazards ModelsRecombinant ProteinsRisk AssessmentSex FactorsSurvival AnalysisThrombolytic TherapyTreatment OutcomeConceptsST-elevation myocardial infarctionElevation myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary percutaneous coronary interventionIIb/IIIa inhibitorsBaseline anemiaPercutaneous coronary interventionAdjunctive antithrombotic therapyMajor bleedingMyocardial infarctionAntithrombotic therapyCoronary interventionUnfractionated heparinST-segment elevation myocardial infarctionMultivariate analysisAcute Myocardial Infarction trialImpact of anemiaMyocardial Infarction trialOutcomes of patientsHarmonizing OutcomesCardiac mortalityCause mortalityLate mortalityPrimary PCIClinical outcomesPredictors of Outcomes in Medically Treated Patients With Acute Coronary Syndromes After Angiographic Triage
Goto K, Lansky AJ, Fahy M, Cristea E, Feit F, Ohman EM, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Mehran R, Stone GW. Predictors of Outcomes in Medically Treated Patients With Acute Coronary Syndromes After Angiographic Triage. Circulation 2010, 121: 853-862. PMID: 20142447, DOI: 10.1161/circulationaha.109.877944.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeAcute coronary syndrome patientsCoronary syndrome patientsComposite ischemiaCoronary syndromeAngiographic screeningCoronary ectasiaIschemic outcomesJeopardy scoreSyndrome patientsUrgent Intervention Triage Strategy (ACUITY) trialGlycoprotein IIb/IIIa inhibitorsAcute coronary syndrome populationPrevious percutaneous coronary interventionIIb/IIIa inhibitorsComposite ischemic eventsEarly invasive approachAdverse cardiac eventsOutcomes of patientsPercutaneous coronary interventionPredictors of outcomeTraditional clinical parametersAcute CatheterizationBivalirudin therapyMajor bleeding
2009
Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications
Pocock SJ, Mehran R, Clayton TC, Nikolsky E, Parise H, Fahy M, Lansky AJ, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Stone GW. Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications. Circulation 2009, 121: 43-51. PMID: 20026777, DOI: 10.1161/circulationaha.109.878017.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAged, 80 and overFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansLogistic ModelsMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial IschemiaPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexPredictive Value of TestsPrognosisRandomized Controlled Trials as TopicRecombinant ProteinsRetrospective StudiesRisk FactorsConceptsGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsIndividual patient risk profileAcute coronary syndromePatient risk profileMajor bleedingMyocardial infarctionCoronary syndromeRisk profileHemorrhagic complicationsIndependent predictorsMortality rateUrgent Intervention Triage Strategy (ACUITY) trialAlternative antithrombotic regimensIndividual patient's riskRisk of deathCox regression modelTherapy of patientsSubsequent mortality ratesRelative treatment effectsAcute CatheterizationAntithrombotic regimensMajor bleedsAlternative pharmacotherapyStrategy trialBivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial
Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW, Investigators F. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. The Lancet 2009, 374: 1149-1159. PMID: 19717185, DOI: 10.1016/s0140-6736(09)61484-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsFemaleFollow-Up StudiesHemorrhageHeparinHirudinsHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProportional Hazards ModelsRecombinant ProteinsStentsSurvival RateThrombosisTreatment OutcomeConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionNet adverse clinical eventsPercutaneous coronary interventionAdverse clinical eventsBivalirudin groupMajor bleedingClinical eventsControl groupMyocardial infarctionAcute ST-segment elevation myocardial infarctionIIb/IIIa inhibitorsPrimary percutaneous coronary interventionHORIZONS-AMI trialMajor haemorrhagic complicationsPrimary trial endpointRate of MACERate of NACEElevation myocardial infarctionOnset of symptomsAcute myocardial infarctionOptimum treatment strategyWithdrawal of consentThrombin inhibitor bivalirudinImportant clinical implicationsImpact of Chronic Kidney Disease on Early (30-Day) and Late (1-Year) Outcomes of Patients With Acute Coronary Syndromes Treated With Alternative Antithrombotic Treatment Strategies An ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Substudy
Mehran R, Nikolsky E, Lansky AJ, Kirtane AJ, Kim YH, Feit F, Manoukian S, Moses JW, Ebrahimi R, Ohman EM, White HD, Pocock SJ, Dangas GD, Stone GW. Impact of Chronic Kidney Disease on Early (30-Day) and Late (1-Year) Outcomes of Patients With Acute Coronary Syndromes Treated With Alternative Antithrombotic Treatment Strategies An ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Substudy. JACC Cardiovascular Interventions 2009, 2: 748-757. PMID: 19695543, DOI: 10.1016/j.jcin.2009.05.018.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryBiomarkersChronic DiseaseCoronary Artery BypassCreatinineDrug Therapy, CombinationFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansKidney DiseasesLogistic ModelsMaleMiddle AgedMyocardial InfarctionMyocardial IschemiaOdds RatioPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRecombinant ProteinsRisk AssessmentTime FactorsTreatment OutcomeTriageConceptsGlycoprotein IIb/IIIa inhibitorsChronic kidney diseaseAcute coronary syndromeBivalirudin monotherapyComposite ischemiaMajor bleedingCoronary syndromeClinical outcomesKidney diseaseHigh-risk acute coronary syndromesIIb/IIIa inhibitorsClinical adverse outcomesCreatinine clearance dataOutcomes of patientsNormal renal functionAdverse event ratesAntithrombotic treatment strategiesSignificant differencesACUITY trialIschemic outcomesRenal functionAdverse outcomesInvasive strategyLate outcomesTreatment strategies